Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
SAN FRANCISCO (AFX) - GlaxoSmithKline said a new mathematical model of data for its Cervarix cancer vaccine shows a 70 pct prevention of cervical cancer cases and deaths.
The prevention assumes total vaccine coverage of all 12-year-old girls in the US against HPV types 16 and 18.
The drug company said that when the model factors in potential additional protection against other cancer-causing HPV types, vaccination may prevent an estimated 80 pct of cervical cancer cases and deaths in the US.
The hypothetical model is based in part on published clinical data that demonstrated that GlaxoSmithKline's cervical cancer vaccine candidate, Cervarix, may provide broader protection.
Cervarix was developed to prevent infection and lesions from the two most prevalent cancer-causing types of HPV, specifically HPV 16 and 18. newsdesk@afxnews.com ks COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Copyright 2006 AFX News Limited. All Rights Reserved.
